Displaying 25 - 36 of 83
Viral Hepatitis
1

GlaxoSmithKline: Nothing about me without me - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Viral Hepatitis
6

AbbVie: An HCV-Free Future - It Always Seems Impossible Until It's Done - ILC 2022

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Displaying 25 - 36 of 83